Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
作者：
Laukhtina E.
Mori K.
Mostafaei H.
Merseburger A. S.
Nyirady P.
Moschini M.
Quhal F.
Schuettfort V. M.
Pradere B.
Motlagh R. S.
Enikeev D.
Shariat S. F.
Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group E. A.
作者单位：
Department of Urology, Hôpital Foch, UVSQ-Université Paris-Saclay, Suresnes, France
INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: mathieu.rouanne@gustaveroussy.fr. Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Department of Radiation Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Experimental Cancer Medicine Centre Barts Cancer Institute, Queen Mary University of London, St Bartholomew's Hospital, London, UK.
归属分类：
膀胱肿瘤治疗及预后证据
DOI：
10.1371/journal.pone.0254433
关键词：
Bladder cancer
blood transfusion
cystectomy
oncology
prognostic marker
urothelial carcinoma
OBJECTIVE: Human Epidermal Growth Factor Receptor 2 (HER2) is highly expressed in multiple malignancies and associated with patients' prognosis, but its role in bladder cancer (BCa) remains elusive. We conducted this meta-analysis to explore the clinical significance and prognostic value of HER2 in BCa. METHODS: PubMed was searched for studies published between January 1, 2000 and January 1, 2020. The odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were used to investigate the relationship between HER2 and BCa pathological features. TCGA was mined for the information regarding as well. RESULTS: Our study included 14 articles enrolling 1398 people. Expression of HER2 is higher in bladder cancer than in normal tissues. HER2 over-expression is associated with CIS, multifocal tumor, large tumor size, high tumor stage and grade, lymph node metastasis, progression, recurrence and papillary tumor. We could not find a significant association between HER2 expression and survival time in BCa patients. CONCLUSIONS: Our meta and bioinformatic analysis indicated that HER2 expression was related to pathological malignancy and poor prognosis in BCa.